Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Alexander N. Howell, Rima I. Ghamrawi, Lindsay C. Strowd & Steven R. Feldman. (2020) Pharmacological management of atopic dermatitis in the elderly. Expert Opinion on Pharmacotherapy 21:7, pages 761-771.
Read now
Read now
Hanna Prucha, Christina Schnopp, Cezmi Akdis, Roger Lauener, Andreas Wollenberg, Johannes Ring & Claudia Traidl-Hoffmann. (2013)
Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema. Expert Opinion on Drug Metabolism & Toxicology 9:11, pages 1507-1516.
Read now
Read now
Jean Ayer & Helen S Young. (2013)
Pimecrolimus for psoriasis. Expert Opinion on Pharmacotherapy 14:6, pages 767-774.
Read now
Read now
Jan Ehrchen, Cord Sunderkötter, Thomas Luger & Martin Steinhoff. (2008) Calcineurin inhibitors for the treatment of atopic dermatitis. Expert Opinion on Pharmacotherapy 9:17, pages 3009-3023.
Read now
Read now
Edwin J. M. Van Leent, Henry J. C. De Vries, Marie‐Eve Ebelin, Pascale Burtin, Graham Scott & Jan D. Bos. (2007) Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel®) for up to 1 year. Journal of Dermatological Treatment 18:1, pages 19-22.
Read now
Read now
David C Swinney. (2006) Opportunities to minimise risk in drug discovery and development. Expert Opinion on Drug Discovery 1:7, pages 627-633.
Read now
Read now
Neslihan Şendur, Göksun Karaman, Nagehan Saniç & Ekin Şavk. (2006) Topical pimecrolimus: A new horizon for vitiligo treatment?. Journal of Dermatological Treatment 17:6, pages 338-342.
Read now
Read now
Klaus Wolff & Anton Stuetz. (2004) Pimecrolimus for the treatment of inflammatory skin disease. Expert Opinion on Pharmacotherapy 5:3, pages 643-655.
Read now
Read now
Fulvio Mastrandrea. (2001) Immunotherapy in atopic dermatitis. Expert Opinion on Investigational Drugs 10:1, pages 49-63.
Read now
Read now
Articles from other publishers (46)
Odeh Alsmeirat, Som Lakhani, Musab Egaimi, Osama Idris & Mohamed Elkhalifa. (2022) The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials. Cureus.
Crossref
Crossref
Mingshan Li, Lalitkumar K. Vora, Ke Peng & Ryan F. Donnelly. (2022) Trilayer microneedle array assisted transdermal and intradermal delivery of dexamethasone. International Journal of Pharmaceutics 612, pages 121295.
Crossref
Crossref
Lateef Babatunde Salam, Oluwafemi S. Obayori & Mutiat O. Mohammed. (2021) Detection of biosynthetic genes of microbially-synthesized secondary metabolites in a contaminated tropical agricultural soil. Biologia 76:11, pages 3449-3464.
Crossref
Crossref
Sai Yee Chuah & Boon Kee Goh. 2018. Vitiligo. Vitiligo
133
140
.
Ludger A. Wessjohann, Richard Bartelt & Wolfgang Brandt. 2017. Practical Medicinal Chemistry with Macrocycles. Practical Medicinal Chemistry with Macrocycles
77
100
.
Ruben Vardanyan. 2017. Piperidine-Based Drug Discovery. Piperidine-Based Drug Discovery
103
125
.
Thomas A. Luger, Ian McDonald & Martin Steinhoff. 2017. Clinical and Basic Immunodermatology. Clinical and Basic Immunodermatology
791
802
.
Khalifa E. Sharquie, Hayder R. Al-Hamamy, Adil A. Noaimi & Kholod A. Ali. (2015) Treatment of Localized Vitiligo with 1% Pimecrolimus Cream versus 0.05% Clobetasol Propionate Cream—Single, Blinded, Comparative Therapeutic Trial. Journal of Cosmetics, Dermatological Sciences and Applications 05:02, pages 107-115.
Crossref
Crossref
Preeti Vaishnav, Young J. Yoo, Yeo J. Yoon & Arnold L. Demain. 2014. Bioactive Natural Products. Bioactive Natural Products
43
82
.
Arnold L Demain. (2014) Importance of microbial natural products and the need to revitalize their discovery. Journal of Industrial Microbiology and Biotechnology 41:2, pages 185-201.
Crossref
Crossref
David C. Swinney. 2011. Label‐Free Technologies for Drug Discovery. Label‐Free Technologies for Drug Discovery
283
302
.
Ali A. Al Raddadi, Mohammad I. Fatani, Yasir H. Shaikh, Diamant Thaci, Abdullah A. Al Reshaid, Abdullah M. Al-Eisa, Walid A. Alghamdi, Hassan Y. Abdulfattah, Zohir M. Al Belbisi, Ali C. Atawi, Waleed A. Alajroush, Abdullah A. Al Fadly, Said I. El-Shamy, Sameer K. Zimmo, Abdullah A. Alqahtani, Majdy M. Abdulghani, Khaled M. Al Abod, Khaled M. Al Attas, Mohamad F. Al Ayouby, Mohammed S. Qari & Adel S. Al Ghanim. (2011) Adopted guidelines of care for the topical management of psoriasis from American and German guidelines. Journal of the Saudi Society of Dermatology & Dermatologic Surgery 15:1, pages 5-13.
Crossref
Crossref
Khalid A. Al Johani, Anne M. Hegarty, Stephen R. Porter & Stefano Fedele. (2009) Calcineurin inhibitors in oral medicine. Journal of the American Academy of Dermatology 61:5, pages 829-840.
Crossref
Crossref
Bethany A. Cook & Erin M. Warshaw. (2009) Role of Topical Calcineurin Inhibitors in the Treatment of Seborrheic Dermatitis. American Journal of Clinical Dermatology 10:2, pages 103-118.
Crossref
Crossref
C. O. Mensing, C. H. Mensing & H. Mensing. (2008) Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck. International Journal of Dermatology 47:9, pages 960-964.
Crossref
Crossref
Thomas A Luger & Martin Steinhoff. 2008. Textbook of Atopic Dermatitis. Textbook of Atopic Dermatitis
247
260
.
Thomas A. Luger & Martin Steinhoff. 2008. Clinical and Basic Immunodermatology. Clinical and Basic Immunodermatology
539
549
.
Torsten Zuberbier, Lucie Heinzerling, Thomas Bieber, Uwe Schauer, Sven Klebs & Matthias Bräutigam. (2007) Steroid-Sparing Effect of Pimecrolimus Cream 1% in Children with Severe Atopic Dermatitis. Dermatology 215:4, pages 325-330.
Crossref
Crossref
Meret E. Ricklin Gutzwiller, Martin Reist, Elke Persohn, John E. Peel & Petra J. Roosje. (2006) Penetration of ASM 981 in canine skin: a comparative study. European Journal of Drug Metabolism and Pharmacokinetics 31:2, pages 53-58.
Crossref
Crossref
Doris Staab, David Pariser, Alice B. Gottlieb, Roland Kaufmann, Laurence F. Eichenfield, Richard G. Langley, Graham Scott, Marie-Eve Ebelin, Denise Barilla, Heinz Schmidli & Pascale Burtin. (2005) Low Systemic Absorption and Good Tolerability of Pimecrolimus, Administered as 1% Cream (ElidelR) in Infants with Atopic Dermatitis - A Multicenter, 3-Week, Open-Label Study. Pediatric Dermatology 22:5, pages 465-471.
Crossref
Crossref
D. Simon, E. Vassina, S. Yousefi, L. R. Braathen & H.-U. Simon. (2005) Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 60:7, pages 944-951.
Crossref
Crossref
A. Taïeb & F. Boralevi. (2005) Nouveaux traitements de la dermatite atopique. Archives de Pédiatrie 12:4, pages 491-497.
Crossref
Crossref
Kristine Breuer, Thomas Werfel & Alexander Kapp. (2005) Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Childhood Atopic Dermatitis. American Journal of Clinical Dermatology 6:2, pages 65-77.
Crossref
Crossref
Kresimir Kostovic & Aida Pasic. (2005) New Treatment Modalities for Vitiligo. Drugs 65:4, pages 447-459.
Crossref
Crossref
Kristine Breuer, Thomas T Werfel & Alexander Kapp. (2005) Pimecrolimus for the treatment of atopic dermatitis. Therapy 2:1, pages 37-56.
Crossref
Crossref
Arnold L. Demain & Lixin Zhang. 2005. Natural Products. Natural Products
3
29
.
Klaus Wolff. (2004) Current concepts and review of pimecrolimus in the treatment of psoriasis. Dermatologic Clinics 22:4, pages 461-465.
Crossref
Crossref
K. C. Bhol, J. Alroy & P. J. Schechter. (2004) Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model. Clinical and Experimental Dermatology 29:3, pages 282-287.
Crossref
Crossref
K. Breuer, A. Kapp & T. Werfel. (2004) Topical immunomodulators in the treatment of atopic dermatitis / Topische Immunmodulatoren bei der Behandlung der atopischen Dermatitis. LaboratoriumsMedizin 28:3, pages 284-287.
Crossref
Crossref
AK Gupta & M Chow. (2003) Pimecrolimus: A review. Journal of the European Academy of Dermatology and Venereology 17:5, pages 493-503.
Crossref
Crossref
Pia Freyschmidt-Paul, Rudolf Happle, Kevin J. McElwee & Rolf Hoffmann. (2003) Alopecia Areata: Treatment of Today and Tomorrow. Journal of Investigative Dermatology Symposium Proceedings 8:1, pages 12-17.
Crossref
Crossref
RAC Graham‐Brown & M Grassberger. (2003) PIMECROLIMUS: A REVIEW OF PRE‐CLINICAL AND CLINICAL DATA. International Journal of Clinical Practice 57:4, pages 319-327.
Crossref
Crossref
Nordwig S Tomi & Thomas A Luger. (2003) The treatment of atopic dermatitis with topical immunomodulators. Clinics in Dermatology 21:3, pages 215-224.
Crossref
Crossref
Graham Scott, Stuart A Osborne, Gerard Greig, Stefan Hartmann, Marie-Eve Ebelin, Pascale Burtin, Klemens Rappersberger, Michael Komar & Klaus Wolff. (2003) Pharmacokinetics of Pimecrolimus, a Novel Nonsteroid Anti-Inflammatory Drug, After Single and Multiple Oral Administration. Clinical Pharmacokinetics 42:14, pages 1305-1314.
Crossref
Crossref
Cécile Boyer-Joubert, Edwige Lorthiois & François Moreau. 2003.
347
374
.
Klemens Rappersberger, Michael Komar, Leo Richter, Klaus Wolff, Marie-Eve Ebelin, Graham Scott, Pascale Burtin, Gerard Greig, Jeanne Kehren, Salah-Dine Chibout, Andre Cordier, Wolfgang Holter, Rainer Oberbauer & Anton Stuetz. (2002) Pimecrolimus Identifies a Common Genomic Anti-inflammatory Profile, is Clinically Highly Effective in Psoriasis and is Well Tolerated. Journal of Investigative Dermatology 119:4, pages 876-887.
Crossref
Crossref
F S KALTHOFF, J CHUNG & A STUETZ. (2002) Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clinical and Experimental Immunology 130:1, pages 85-92.
Crossref
Crossref
K. Baumann, K. Högenauer, G. Schulz & A. Steck. (2002)
NMR study on 9‐
S
and 9‐
R
oxirane derivatives of ascomycin
. Magnetic Resonance in Chemistry 40:7, pages 443-448.
Crossref
Crossref
A Taïeb. (2002) Immunomodulation et dermatite atopique. Revue Française d'Allergologie et d'Immunologie Clinique 42:4, pages 367-372.
Crossref
Crossref
Ulrich R. Hengge. (2008) Topische Immunmodulation in der Dermatologie. H&G Zeitschrift für Hautkrankheiten 77:3, pages 116-130.
Crossref
Crossref
Keri Wellington & Blair Jarvis. (2002) Topical Pimecrolimus. Drugs 62:5, pages 817-840.
Crossref
Crossref
Anton Stuetz, Maximilian Grassberger & Josef G. Meingassner. (2001) Pimecrolimus (Elidel, SDZ ASM 981)—Preclinical pharmacologic profile and skin selectivity. Seminars in Cutaneous Medicine and Surgery 20:4, pages 233-241.
Crossref
Crossref
Adelaide A. Hebert, Kristyn Anne Warken & Robert Cherill. (2001) Pimecrolimus cream 1%: A new development in nonsteroid topical treatment of inflammatory skin diseases. Seminars in Cutaneous Medicine and Surgery 20:4, pages 260-267.
Crossref
Crossref
Torsten Zuberbier, Sie-Uen Chong, Karl Grunow, Sven Guhl, Pia Welker, Maximilian Grassberger & Beate M. Henz. (2001) The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. Journal of Allergy and Clinical Immunology 108:2, pages 275-280.
Crossref
Crossref
C.E.M. Griffiths. (2001) Ascomycin: an advance in the management of atopic dermatitis. British Journal of Dermatology 144:4, pages 679-681.
Crossref
Crossref
Thomas A. Luger. 2001. Fortschritte der praktischen Dermatologie und Venerologie. Fortschritte der praktischen Dermatologie und Venerologie
67
74
.